Possible implication of the effector CD4+ T-cell subpopulation TH17 in the pathogenesis of systemic scleroderma
- 11 September 2007
- journal article
- Published by Springer Nature in Nature Clinical Practice Rheumatology
- Vol. 3 (12) , 682-683
- https://doi.org/10.1038/ncprheum0618
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Systemic sclerosis: a prototypic multisystem fibrotic disorderJournal of Clinical Investigation, 2007
- Expression and regulation of IL-22 in the IL-17-producing CD4+ T lymphocytesCell Research, 2006
- Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptidesThe Journal of Experimental Medicine, 2006
- Double‐blind randomized controlled clinical trial of the interleukin‐6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexateArthritis & Rheumatism, 2006
- Mechanisms and consequences of fibrosis in systemic sclerosisNature Clinical Practice Rheumatology, 2006
- TH-17: a giant step from TH1 and TH2Nature Immunology, 2005
- Is systemic sclerosis an antigen‐driven T cell disease?Arthritis & Rheumatism, 2004
- Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 The Journal of Experimental Medicine, 2003
- Control of Regulatory T Cell Development by the Transcription Factor Foxp3Science, 2003
- Increased interleukin-17 production in patients with systemic sclerosisArthritis & Rheumatism, 2000